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Introduction
Oligometastatic breast disease is a potentially curable state of distant cancer spread, but there is still no standard approach 
for treatment. The aim of this article is to present a clinical case of oligometastatic breast cancer and short data of the latest 
literature sources.
Case report
This case report presents 58 years old postmenopausal women diagnosed with oligometastatic breast carcinoma who under-
went a successful simultaneous nipple-sparing mastectomy with sentinel node biopsy and right upper lobectomy in National 
Cancer Institute, Vilnius, Lithuania. 
Conclusions
Multidisciplinary approach and modern imaging studies allows us to diagnose and successfully treat this rare pathological 
state. Scientific trials to delineate proper indications for oligometastatic breast disease are needed 
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Įvadas
Oligometastazinis krūties vėžys yra potencialiai pagydoma būklė, kuriai yra būdingas ribotas metastazinis išplitimas, tačiau 
iki šiol nėra gydymo standartų. Straipsnio tikslas – aprašyti retą oligometastazinio krūties vėžio atvejį, apžvelgti naujausius 
literatūros šaltinius ir įvertinti problemos aktualumą.
Klinikinis atvejis
Straipsnyje aprašomas 58 metų moters klinikinis atvejis – postmenopauzės laikotarpiu jai buvo diagnozuotas oligometasta-
zinis krūties vėžys. Ligonė buvo gydyta chirurginiu būdu Nacionaliniame vėžio institute Vilniuje.
118 V .  O s t a p e n k o ,  S .  C i c ė n a s ,  A .  O s t a p e n k o ,  R .  B r i e d i e n ė ,  E .  O s t a p e n k o
Išvados
Moderni radiologinė diagnostika ir daugiadalykės komandos darbas sudaro galimybes sėkmingai diagnozuoti ir gydyti šią 
retą onkologinę patologiją. Ateityje reikalingi moksliniai tyrimai oligometastazinio krūties vėžio gydymui standartizuoti. 
Reikšminiai žodžiai: oligometastazinė liga, krūties vėžys, daugiadalykės komandos darbas
Introduction
Oligometastatic (OM) breast cancer (BC) – is a disease 
concept, which is defined by a state of limited systemic 
metastatic tumors. Limited means 1 to 5. These me-
tastases are typically confined to one organ. In case we 
have more than 5 metastases it is a risk that tumor cells 
may acquire widespread metastatic potential. Multi-
disciplinary approach and modern imaging studies 
allows us to diagnose and treat this rare pathological 
state. Oligometastatic breast cancer differs from multi-
metastatic diseases in prognosis and survival rate. The 
identification of patients with oligometastatic disease 
is very important, because oligometastatic disease is a 
potentially curable state of distant cancer spread. 
Case report 
58 years old white postmenopausal woman complained 
the lump in her left breast. Woman found the lump 
during her monthly self-examination. Further patient 
examinations and treatment was performed in National 
Cancer Institute, Vilnius, Lithuania
Breast physical examination: in the upper quadrant of 
the left breast a palpable, freely movable, mass measures 
~3 cm in diameter. No pain or tenderness; no nipple 
discharge; no skin changes, no nipple retraction. Left 
breast: no palpated masses. Axillary and regional lymph 
nodes – not enlarged. 
The radiologic examination of this patient included: 
breast ultrasound, digital mammography, MRI, ul-
trasonography guided core breast biopsy, whole body 
CT scan, PET CT. The ultrasonography (Fig. 1) was 
performed, and mammography suggested a malignant 
mass (Bi-rads-V) (Fig. 2 and Fig. 3). 
Additional radiologic examination (whole body 
MRI, PET CT scan) revealed a 2.5 cm tumor in an up-
per lobe of the right lung and metastatic lesions in a left 
iliac bone body (Fig. 4, Fig. 5, Fig. 6).
Preoperative breast and lung tumors biopsy was per-
formed and invasive breast ductal carcinoma G2 HER2 
positive 1+, ER negative 100% PR positive 80% , Ki-67 – 
10% and lung adenocarcinoma G2 was confirmed. 
Oligometastatic left breast carcinoma cT2N×M1 
stage IV with metastasis to bones and peripheral upper 
Figure 1. Ultrasonogram of breast pathological mass ~17mm. Elastography 
shows hard tissue (blue color)
Figure 2. Right breast: 
mediolateral oblique 
view of normal breast
Figure 3. Left breast: 20 mm 
pathological mass with micro-
calcinates grouped in the left 
upper quadrant
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Figure 4. Whole body MRI 
scan reveals perfectly visible 
tumor in right lung
Figure 5. PET CT scan reveals slightly seen bone metastatic 
lesions/infiltration of left iliac body
Figure 6. PET CT scan reveals perfectly visible tumor in right 
lung
lobe of the right lung carcinoma cT2N×M0 stage II were 
diagnosed and preoperative diagnosis was confirmed 
histologically by core biopsy. According to the extent of 
the oncologic disease and biologic type of breast cancer 
(luminal A), multidisciplinary team recommended 
simultaneous right lobectomy and left nipple sparing 
mastectomy with sentinel lymph node biopsy. 
In April of 2016 combined simultaneous left nipple 
sparing mastectomy with sentinel node biopsy and up-
per right lobectomy were performed.
Postoperative diagnosis: oligometastatic left breast 
carcinoma pT2N0(sn)M1 stage IV. Metastasis to left 
iliac bone. Peripherial carcinoma in the right lung L1, 
pT1bN0M0 stage I. 
Now patient is recovering in the rehabilitation clinic 
after surgery. Breast multidisciplinary team recom-
mended whole body CT and adjuvant hormonotherapy 
for breast cancer treatment. After full body CT evalua-
tion and rehabilitation – final breast and thoracic mul-
tidisciplinary team evaluation. 
Discussion
The oligometastatic state implies that a few metastases 
(usually ≤ 5) exist before tumor cells acquire widespread 
metastatic potential [2]. Clinically, OM BC is char-
acterized by solitary or few detectable lesions, usually 
limited to single organs, in which local therapy could 
affect survival. This population of ‘potentially curable’ 
stage IV disease is estimated to be 1–10% of newly di-
agnosed patients with metastatic BC [1]. Patients with 
OM disease can be divided into 3 cohorts [3, 4]: those 
who present with oligometastases; those with residual 
oligometastases after systemic therapy (ST); those with 
relapsed oligometastases after curative locoregional 
therapy. Most published series refer to an era before 
modern imaging (i.e. PET CT), and thus many patients 
were probably under-staged. Treatment purpose options 
must be evaluated, before starting treatment. State of 
oligorecurrence means that all the gross tumors could be 
treated with local therapy, meaning curative treatment. 
State of oligometastases means clinicians should judge 
whether a primary site can be controlled. If primary 
site is controlled, meaning oligorecurrence, they should 
pursue to cure the patients. In case primary site is un-
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controlled or extra-target metastases lesions exist, they 
intend to prolong survival not to pursue cure [5, 8].
Multidisciplinary approach and modern imaging 
studies allows us to diagnose and treat this rare patho-
logical state. Improved modern imaging and aggressive 
approaches are recommended in patients with only ap-
parently limited disease [6].
Oligometastatic breast cancer differs from multi-
metastatic diseases in prognosis and survival rate. The 
identification of patients with oligometastatic disease 
is very important, because oligometastatic disease is a 
potentially curable state of distant cancer spread. Sur-
Figure 7. Scheme 1 shows one distant metastasis with a 
primary lesion. Scheme 2 shows two distant metastases with a 
primary lesion
Scheme of oligo-recurrence
Figure 8. Scheme 1 shows one distant recurrence with a con-
trolled primary lesion. Scheme 2 shows two distant recurrences 
with a controlled primary lesion 
Scheme of oligo-metastases
vival rate of this narrow group of oligometastatic cancer 
patients are impressive: the local control at 3 years 89%, 
overall survival at 3 years 73% [7].
Conclusions
Oligometastatic breast cancer disease is a potentially 
curable state of distant cancer spread. There is still 
no standard approach for treatment. Every patient is 
unique and requires specific multidisciplinary approach. 
The identification of patients with oligometastatic dis-
ease is very important. 
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